ATNM

Actinium Pharmaceuticals, Inc. (ATNM) ESG Analysis Analysis (2026)

Invetso Score: 6.5/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 6.2 (Moderate)

ATNM’s very high R&D intensity versus revenue suggests a science-led operating model, but peer-relative environmental benefits are limited without disclosed emissions or resource metrics.

Low leverage reduces balance-sheet pressure, which can support longer-horizon environmental investment, yet peers with similar capital structures may show comparable flexibility.

The provided metrics do not disclose energy use, waste, or climate targets, leaving ATNM’s environmental positioning less evidenced than peers with fuller sustainability reporting.

A research-focused cost base can align with lower physical footprint than manufacturing peers, but the absence of verified operational data prevents a stronger relative score.

Social

Score:

ATNM’s low stock-based compensation as a share of revenue indicates limited dilution pressure, which can support employee alignment, though peers often disclose broader workforce metrics.

High R&D intensity implies dependence on specialized scientific talent, but the lack of turnover, safety, or diversity disclosure makes peer comparison incomplete.

No disclosed product-access, patient, or community metrics are provided, so ATNM cannot be shown to outperform peers on social impact transparency.

The company’s small leverage burden may reduce restructuring risk for employees, yet social positioning remains only moderate because key workforce indicators are missing.

Governance

Score:

Very low debt-to-equity suggests conservative capital structure, which can reduce creditor-driven governance pressure relative to more levered peers.

Stock-based compensation is modest versus revenue, indicating restrained equity dilution, although peer leaders typically pair this with clearer disclosure on incentive design.

The absence of board composition, audit, and shareholder-rights data limits confidence that ATNM’s governance is stronger than peers with more complete filings.

Negative net debt to EBITDA indicates liquidity support, but governance assessment remains moderate because the provided metrics do not address oversight quality directly.

Overall Score

Score:

ATNM screens as a moderate ESG name versus peers because conservative leverage and restrained dilution help, but limited disclosure prevents a stronger relative assessment.

Score Driver: Limited ESG Disclosure Versus Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Actinium Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →